Skip to main content
. 2020 Aug 19;38(28):3282–3293. doi: 10.1200/JCO.20.00256

FIG A1.

FIG A1.

Disease-free survival (DFS) for patients with CNS3 randomly assigned to high-dose methotrexate with leucovorin rescue (HDMTX) with or without nelarabine; 5-year DFS rates were 93.1% ± 6.5% for HDMTX with nelarabine and 67.9% ± 12.2% for HDMTX without nelarabine (P = .014).